SAN FRANCISCO, March 1, 2018 /PRNewswire/ --
The global molecular cytogenetics market size is expected to reach USD 3. 8 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a 10.4% CAGR during the forecast period. Mapping of human genome, coupled with continuous technological advancements in cytogenetic techniques, has enabled researchers to gain insight into the disease-causing mechanism at a genomic as well as cellular level. Development in molecular technologies has helped in bridging the gap between molecular biology and cytogenetics, which was not possible using conventional cytogenetic techniques.
(Logo: http://photos.prnewswire.com/prnh/20160524/371361LOGO )
There is a continuous growth in awareness, and consequent adoption, of genetic tests for disease prognosis. These tests also help in designing further treatment regimes for widespread chromosomal abnormalities. This is sure to boost market growth.
Incorporation of high throughput sequencers in cytogenetic analysis is expected to significantly enhance market growth in the coming years. A number of researchers and scientists have begun converging cytogenetics laboratories with NGS as they complement each other. Hence, with exponential decline in sequencing price, this market is expected to grow at a lucrative pace.
However, ambiguous regulatory and reimbursement scenario in certain regions pertaining to implementation of genetic tests is expected to hamper the adoption of molecular cytogenetic techniques to a certain extent.
Browse full research report with TOC on "Molecular Cytogenetics Market Analysis Report By Application (Oncology, Personalized Medicine), By Product, By End Use, By Technology (FISH, Immunochemistry, Karyotyping), And Segment Forecasts, 2014 - 2025" at: https://www.grandviewresearch.com/industry-analysis/molecular-cytogenetics-market
Further Key Findings From the Report Suggest:
- Oncology held the largest share in the market in 2016 owing to the ability of CGH technology to facilitate in-depth studies for cancer etiology
- Use of molecular cytogenetics in personalized medicine development is expected to grow lucratively during the forecast period. This is majorly due to a continuous shift toward targeted therapies for effective disease management
- Requirement of consumables in the entire cytogenetics process is attributive for the largest share of this product category
- Ongoing research projects for developing treatment regimen of different genetic conditions have allowed clinical and research laboratories to gain a significant share in the market
- Pharmaceutical and biotech companies are expected to be a key source of revenue in the coming years. This is mainly because a number of pharmaceutical companies have expanded their business in the field of personalized medicine
- Illumina, Inc.; Agilent Technologies, Inc.; Abbott; Bio-Rad Laboratories, Inc.; and Oxford Gene Technology are some prominent companies in the market. They are involved in development and commercialization of cytogenetics techniques
- Some major service providers are Weill Cornell Medicine; WiCell Research Institute, Inc.; ARUP Laboratories; and Integrated Systems Engineering S.r.l.
Browse related reports by Grand View Research:
- Virology Market - Virology is the branch of Microbiology or Pathology. Virology is the study of viruses, i.e. Submicroscopic, parasitic particles of genetic material contained in a protein coat and virus-like agents.
- Aminoglycosides Market - The global aminoglycosides market size was valued to be over USD 1.1 billion in 2014 and is expected to witness a growth of over 3.0% CAGR in the coming years owing to rising incidence of bacterial infections.
- Continuous Glucose Monitoring Devices Market - The continuous glucose monitoring devices market is estimated to account for USD 0.4 billion in 2016.
- Personalized Medicine (PM) Market - The global personalized medicine market was valued at USD 1,007.88 billion in 2014 and is expected to reach USD 2,452.50 billion in 2022, growing at a CAGR of 11.8% over the forecast period.
Grand View Research has segmented the global molecular cytogenetics market on the basis of application, product, end use, technology, and region:
- Molecular Cytogenetics Application Outlook (Revenue, USD Million, 2014 - 2025)
- Genetic Disorders
- Oncology
- Personalized Medicine
- Other Applications
- Molecular Cytogenetics Product Outlook (Revenue, USD Million, 2014 - 2025)
- Instruments
- Consumables
- Software & Services
- Molecular Cytogenetics End-use Outlook (Revenue, USD Million, 2014 - 2025)
- Clinical & Research Laboratories
- Hospitals & Pathology Laboratories
- Academic Research Institutes
- Pharmaceutical and Biotechnology Companies
- Other End-use
- Molecular Cytogenetics Technology Outlook (Revenue, USD Million, 2014 - 2025)
- Comparative Genomic Hybridization
- Array-based comparative genomic hybridization
- Standard comparative genomic hybridization
- Fluorescence In Situ Hybridization (FISH)
- Immunohistochemistry
- Karyotyping
- Spectral karyotyping
- Virtual karyotyping
- Other Techniques
- Comparative Genomic Hybridization
- Molecular Cytogenetics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East & Africa
- South Africa
- North America
Read Our Blog By Grand View Research: https://www.grandviewresearch.com/blogs/healthcare
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Share this article